Brief: Poseida Therapeutics Presents Early Data From Phase 1 Trials Of P-MUC1C-ALLO1, P-BCMA-ALLO1

Poseida Therapeutics

06/12/2022 11:52

Dec 6 (Reuters) - Poseida Therapeutics Inc  PSTX.O :
    * POSEIDA THERAPEUTICS TO PRESENT EARLY DATA FROM PHASE 1
TRIALS
OF P-MUC1C-ALLO1 AND P-BCMA-ALLO1 AT ESMO IMMUNO-ONCOLOGY 2022
ANNUAL CONGRESS
    * POSEIDA THERAPEUTICS - P-MUC1C-ALLO1 SHOWED ENCOURAGING
CLINICAL
ACTIVITY AND OBJECTIVE PARTIAL RESPONSE IN A BREAST CANCER
PATIENT AT LOWEST DOSE
    * POSEIDA THERAPEUTICS INC - P-MUC1C-ALLO1 AND P-BCMA-ALLO1
WERE
WELL TOLERATED, WITH NO DOSE-LIMITING TOXICITIES (DLTS)

Source text for Eikon:  ID:nPn7xwwgBa 
Further company coverage:  PSTX.O 
 ((Reuters.Briefs@thomsonreuters.com;))